The push to transform prostate cancer care just got a significant boost, with Insight Medbotics announcing it has raised $37.2M in Series b funding. The company is building the first MRI-native platform for prostate cancer biopsy and treatment, aiming to provide urologists with a more accurate way to identify and target lesions.
Its Glenn™ platform, which includes an MRI-compatible robot, is the only one to receive FDA 510(k) clearance for use of a robot with MRI, positioning Insight Medbotics to advance the standard of care.
